Connect Biopharma Holdings Ltd (CNTB): R&D Expense
$37.80M
Year ended 2025-12-31
$53.70M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.80M | +29.2% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $29.26M | -44.8% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $53.00M | n/a | 2025-03-31, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $10.75M | -16.6% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $21.12M | -29.7% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| iBio, Inc. (IBIO) | 2026-06-30 | $19.64M | +136.3% |
Compare CNTB, INO, AVTX, SILO side by side · Screen every company in Pharmaceutical Preparations ↗